The results of a new study highlight the value of tailoring drug treatment to an individual’s genetic makeup. The pharmacogenetics clinical trial study by Green Shield Canada and the health benefits management division of HBM+ followed more than 200 outpatients who had been diagnosed with major mental-health conditions, including depression and anxiety. Participants were randomly […]
On May 12, Benefits Canada hosted a webinar to discuss the pharmaceutical industry’s efforts during the coronavirus crisis, as well as some key policy issues for Canadian insurers and their potential impact from the private-payer perspective. Since the end of April, 139 coronavirus treatments have been under investigation and Health Canada has approved several clinical trials […]
The Patented Medicine Prices Review Board will publish a new draft of its guidelines on June 15, followed by a written consultation period for 30 days. As a result, the amended regulations will be delayed from July 1, 2020 to Jan. 1, 2021. The PMPRB said more details on the next and final phase of […]
Green Shield Canada is investing in Canadian pharmacogenetics company GenXys Health Care Systems. The two companies will be collaborating on new pharmacogenetic products, which are set to launch later this year, with a focus on driving more informed prescribing, fewer adverse drug reactions and better health outcomes for patients and plan members. “GSC has a […]
Plan sponsors and insurers are increasingly wading into the waters of pharmacogenetic testing by offering the service to employees making long-term disability claims. In 2017, Sun Life partnered with the Centre for Addiction and Mental Health for a pilot project that offered pharmacogenetic testing to plan members on disability leave due to a mental-health condition. […]
Does your organization’s benefits or pension plan communications deserve recognition? Are you leading the way when it comes to supporting your employees’ mental health? Is your company’s financial wellness program award-worthy? Benefits Canada’s annual Workplace Benefits Awards is officially open for nominations. Submit your entries here. As in previous years, the 2020 awards will continue to honour the achievements of […]
With providers of dental and paramedical services closed, many aspects of the benefits plans are seeing reduced use. But drug plan spending is continuing unabated — and experts say new concerns are coming up during the crisis. Plan sponsors that have implemented 90-day supplies as a cost-control measure may have to see if their plan can be adapted during […]
Private drug plans saw a slight uptick in costs in 2019 due to the increased use of specialty drugs and higher price points for traditional medications, according to Express Scripts Canada’s annual drug trends report. The report found private drug plan spending per claimant increased one per cent over 2018’s figures. Plans’ annual spend per claimant on […]
On March 3, the 2020 Employers Cancer Care Summit featured sessions on cancer-related issues and opportunities tied to benefits plans and the workplace. Many perspectives required when covering cancer drugs on benefits plans While treatment options for cancer are more than they used to be, many still aren’t covered under the public health-care system, according to Tim […]
While treatment options for cancer are more than they used to be, many still aren’t covered under the public health-care system, according to Tim Clarke, president of TC Health Consulting Inc. In a session at Benefits Canada’s 2020 Employers Cancer Care Summit on Mar. 3, he said employer costs for cancer drug treatments have doubled between […]